Interferon alfa-2a
- Generic Name
- Interferon alfa-2a
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 76543-88-9
- Unique Ingredient Identifier
- 47RRR83SK7
- Background
Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Bioscie...
- Indication
For the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection.
- Associated Conditions
- Chronic Hepatitis B Infection, Chronic Hepatitis C Virus (HCV) Infection, Chronic Myelogenous Leukemia (CML), Cutaneous T-Cell Lymphoma (CTCL), Hairy Cell Leukemia (HCL), Kaposi's Sarcoma, Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), Thrombocytosis
- Associated Therapies
- -
Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone
- Conditions
- Interventions
- First Posted Date
- 2007-02-09
- Last Posted Date
- 2015-05-28
- Lead Sponsor
- University Hospital, Geneva
- Target Recruit Count
- 5
- Registration Number
- NCT00433069
- Locations
- 🇨🇭
Service de Gastroentérologie et d'Hépatologie, University Hospital, Geneva, GE, Switzerland
High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV
- Conditions
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Foundation for Liver Research
- Target Recruit Count
- 33
- Registration Number
- NCT00381953
- Locations
- 🇳🇱
Erasmus Medical Center, Rotterdam, Netherlands
Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-03-06
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT00172809
- Locations
- 🇨🇳
National Taiwan University Hospital, Yun-Lin Branch, Douliou, Taiwan
A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 48
- Registration Number
- NCT00001113
- Locations
- 🇺🇸
Mem Sloan - Kettering Cancer Ctr, New York, New York, United States
A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 56
- Registration Number
- NCT00000725
- Locations
- 🇺🇸
Univ of Miami School of Medicine, Miami, Florida, United States
Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 60
- Registration Number
- NCT00000687
- Locations
- 🇺🇸
Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
🇺🇸Pitt CRS, Pittsburgh, Pennsylvania, United States
A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 132
- Registration Number
- NCT00008463
- Locations
- 🇺🇸
Ucsf Aids Crs, San Francisco, California, United States
🇺🇸The Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hospital ACTG CRS, Boston, Massachusetts, United States
A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 48
- Registration Number
- NCT00000696
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
🇺🇸Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU, New Orleans, Louisiana, United States
A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 60
- Registration Number
- NCT00000754
- Locations
- 🇺🇸
Alabama Therapeutics CRS, Birmingham, Alabama, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
🇺🇸Ucsd, Avrc Crs, La Jolla, California, United States
The Safety of Zidovudine Plus Interferon-Alpha in HIV-Infected Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 52
- Registration Number
- NCT00000967
- Locations
- 🇵🇷
Univ. Hosp. Ramón Ruiz Arnau, Dept. of Peds., Bayamon, Puerto Rico
🇺🇸St. Jude/UTHSC CRS, Memphis, Tennessee, United States
🇵🇷San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.